{
  "id": 14050366,
  "title": "First Tracks climbs on ‘impressive’ celiac study data",
  "url": "https://urgent.news/2026/10/12/first-tracks-climbs-on-impressive-celiac-study-data",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-12T21:26:00.000Z",
  "source": {
    "name": "BioPharma Dive",
    "slug": "biopharma-dive",
    "url": "https://www.biopharmadive.com/news/first-tracks-celiac-study-results-cd122/832726/"
  },
  "original_language": "en",
  "account": null,
  "summary": "Initial study findings strengthened some analysts’ belief that First Tracks’ drug, one of a few in development aimed at the protein CD122, might have “pipeline-in-a-product” potential.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Endpoints News",
        "title": "Mirum succeeds in rare liver disease trial; First Tracks delivers in celiac",
        "url": "https://urgent.news/2026/10/12/mirum-succeeds-in-rare-liver-disease-trial-first-tracks-delivers-in",
        "published": "2026-10-12T15:12:41.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}